<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Growth failure in children with chronic kidney disease: Risk factors, evaluation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Burkhard Tönshoff, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11319558"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Growth failure is a major complication of children with chronic kidney disease (CKD). Poor growth is a marker of disease severity and is associated with significant morbidity and mortality [<a href="#rid1">1,2</a>].</p><p>The impact, pathogenesis, risk factors, evaluation, and diagnosis of growth failure in children with CKD will be reviewed here. The management of growth failure in this population is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/83284.html" rel="external">"Growth failure in children with chronic kidney disease: Prevention and management"</a> and  <a class="medical medical_review" href="/z/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone"</a>.)</p><p class="headingAnchor" id="H113913766"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H113913784"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease revised the 2002 classification of pediatric CKD by the Kidney Disease Outcomes Quality Initiative Clinical Practice Guideline for Chronic Kidney Disease [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Definitions and diagnosis'</a>.)</p><p>The KDIGO guideline also includes CKD staging for children older than two years of age, and stratifies the risk for progression of CKD and its complications based on glomerular filtration rate (GFR). This classification is used to guide management, including what therapeutic interventions should be initiated and when  (<a class="graphic graphic_table graphicRef89808" href="/z/d/graphic/89808.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>G1 – Normal GFR (≥90 mL/min per 1.73 m<sup>2</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span>G2 – GFR between 60 and 89 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3a – GFR between 45 and 59 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3b – GFR between 30 and 44 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G4 – GFR between 15 and 29 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G5 – GFR of less than 15 mL/min per 1.73 m<sup>2</sup> (kidney failure)</p><p></p><p class="headingAnchor" id="H113913869"><span class="h2">Growth measurement</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Z-score</strong> (also called standard deviation score) for height (or length) represents the number of standard deviations (SD) from the mean height values for age. (See  <a class="medical medical_review" href="/z/d/html/5356.html" rel="external">"Measurement of growth in children", section on 'Use of Z-scores'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth velocity</strong> (or height velocity) is the change in growth over time. It is a more sensitive index of growth compared with a single measurement. It is determined by comparing current height/length measurements with previous growth points  (<a class="graphic graphic_figure graphicRef96367" href="/z/d/graphic/96367.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef96366" href="/z/d/graphic/96366.html" rel="external">figure 2</a>).</p><p></p><p class="headingAnchor" id="H11319565"><span class="h1">IMPACT OF POOR GROWTH</span></p><p class="headingAnchor" id="H85209606"><span class="h2">Childhood morbidity and mortality</span><span class="headingEndMark"> — </span>Poor growth in children with CKD, which is a marker of disease severity, is associated with significant morbidity and mortality. This is illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In the first study using data from the United States Renal Data System (USRDS) of 1949 children starting chronic dialysis therapy, multivariate analysis showed the risk of death increased by 14 percent for each unit of decrease of height Z-score [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study using USRDS data of 1112 children undergoing chronic dialysis or who received a kidney transplant from 1990 through 1995, the risk of death increased with growth failure, with a threefold increase in patients with severe growth failure (incremental growth &lt;-3 standard deviation [SD]) and a twofold increase in patients with moderate growth failure (&gt;-3 and &lt;-2 SD) [<a href="#rid6">6</a>]. The hospitalization rate was also greater in patients with moderate and severe growth failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were reported in a study from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) of 2306 children initiated on chronic dialysis between 1992 and 2000 [<a href="#rid7">7</a>]. Multivariate analysis showed the risk of death was twofold higher in patients with heights &lt;1<sup>st</sup> percentile for age compared with patients with heights ≥1<sup>st</sup> percentile. Children with short stature also had decreased school attendance and a greater number of days of hospitalization.</p><p></p><p>Short stature also affects the psychological development of the patient. Short children are often treated as being younger than they are, and particularly in the additional context of chronic illness, may be overprotected and have low expectations set for them [<a href="#rid8">8</a>]. Short stature is associated with poorer school performance, physical functioning, social rehabilitation, and quality of life, as well as lower levels of employment and marital status [<a href="#rid1">1,2,9-11</a>]. Survey data based on parental reports also showed that catch-up growth and the use of growth hormone therapy were associated with higher physical and social functioning [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H359697248"><span class="h2">Final height</span><span class="headingEndMark"> — </span>Poor growth during childhood results in adult short stature. Prior to the use of <a class="drug drug_pediatric" data-topicid="13354" href="/z/d/drug information/13354.html" rel="external">recombinant human growth hormone</a> (rhGH), almost one-half of patients with childhood-onset end-stage kidney disease (ESKD) achieved adult heights below the 3<sup>rd</sup> percentile [<a href="#rid2">2</a>]. The reported final adult height for patients with CKD during childhood is significantly lower than for the normal adult population, with heights for women ranging from 148 to 158 cm (2<sup>nd</sup> percentile 151 cm) and for men between 162 to 168 cm (2<sup>nd</sup> percentile 163 cm) [<a href="#rid12">12</a>]. Final height is most compromised in patients with severe congenital kidney disorders, such as nephropathic cystinosis [<a href="#rid13">13</a>]. Short stature in adulthood contributes to a lower perceived quality of life and self-esteem [<a href="#rid8">8,14</a>].</p><p>Important determinants of final height are older age at start of KRT and kidney transplantation, cumulative time with a functioning graft, and greater standardized height at KRT initiation and kidney transplantation [<a href="#rid6">6,15</a>]. In addition, post-transplant catch-up growth is restricted to the youngest patients (&lt;6 years at kidney transplantation) [<a href="#rid16">16,17</a>].</p><p>Improvement in final height has been observed over time with advancements in the management of pediatric CKD [<a href="#rid3">3</a>]. This was illustrated by an analysis from the European Registry for Children on Renal Replacement Therapy, European Renal Association, and European Dialysis and Transplantation Association registry that showed height increased significantly from -1.93 SD in children who started kidney replacement therapy (KRT) before 1990, to -1.78 SD in children from 1990 to 1999, and to -1.61 SD in those starting KRT after 1999 [<a href="#rid16">16</a>]. Poorest growth outcomes were associated with earlier start and longer duration of dialysis or a diagnosis of a metabolic disorder such as cystinosis and hyperoxaluria. Patients with the best adult final heights were those with a longer time spent with a kidney transplant and who received rhGH therapy. In the United States, final height SD's among over 2500 patients who underwent transplant and reached 19 years of age improved from -1.93 in the period from 1987 to 1991, to -0.89 in the 2007 to 2013 period [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H113913684"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Growth failure is a common problem in children with CKD stages 2 through 5, as illustrated by the following data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry.</p><p class="bulletIndent1"><span class="glyph">●</span>In the 2008 NAPRTCS report, more than 35 percent of children at the time of enrollment in the CKD registry had impaired growth defined as a height less than the 3<sup>rd</sup> percentile for age and sex (Z-score for height below -1.88) [<a href="#rid18">18</a>]. Overall, the mean Z-score for height was -1.44.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In this cohort, the risk of growth failure was greatest in infants (&lt;1 year of age, 58 percent) and lowest in older children (&gt;12 years of age, 22 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk for poor growth increased with decreasing kidney function, although even children with mild kidney impairment (glomerular filtration rate [GFR] &gt;60 mL/min per 1.73 m<sup>2</sup>) were at risk for poor growth  (<a class="graphic graphic_figure graphicRef83841" href="/z/d/graphic/83841.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Growth failure was greater in patients who had been on dialysis for two years with a mean height Z-score of -1.6 [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 2000 recipients enrolled in the transplant NAPRTCS registry who were &gt;19 years of age, one-fourth had significant short stature with a height Z-score less than -2.3, and 10 percent had severe growth failure with a height Z-score less than -3.3 [<a href="#rid18">18</a>].</p><p></p><p>As noted above, final adult height has improved with advancements in the medical and technical management of CKD including kidney replacement therapy (KRT) [<a href="#rid16">16,20-22</a>]. For example, in Germany, the overall mean standardized height in children on KRT has increased from -3.0 standard deviations (SD) in 1988 to -1.8 SD in 2007 [<a href="#rid20">20</a>]. However, in other parts of the world, particularly in those with inadequate local resources, height prognosis remains poor [<a href="#rid16">16,23</a>].</p><p class="headingAnchor" id="H113914234"><span class="h1">PATHOGENESIS: DISTURBANCE OF GROWTH HORMONE/IGF-1 AXIS</span><span class="headingEndMark"> — </span>Although the mechanisms underlying growth failure are not completely understood, clinical and experimental evidence demonstrate that disturbances of growth hormone (GH) metabolism and its main mediator, insulin-like growth factor-1 (IGF-1), are the primary contributing factors for poor growth in children with CKD. Poor nutrition, metabolic acidosis, fluid and electrolyte abnormalities, CKD-related osteodystrophy, and, to a lesser extent, anemia are also important risk factors for growth failure in these children. However, it is only partially known whether and how these factors affect GH/IGF-1 metabolism. (See  <a class="medical medical_review" href="/z/d/html/3802.html" rel="external">"Physiology of growth hormone"</a> and  <a class="medical medical_review" href="/z/d/html/3801.html" rel="external">"Physiology of insulin-like growth factor 1"</a> and <a class="local">'Contributing factors'</a> below.)</p><p>In children with CKD, the following evidence illustrates the primary pathogenetic mechanisms of GH insensitivity and the decreased bioavailability of IGF-1 resulting in growth failure. These data indicate that growth failure in children with CKD is mainly due to functional IGF-1 deficiency [<a href="#rid24">24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with CKD, fasting normal or elevated serum GH levels are disproportionately high for the observed diminished longitudinal growth, which suggests GH insensitivity [<a href="#rid24">24-27</a>]. Data from a uremic rat model that demonstrated a diminished growth response to supraphysiological doses of recombinant growth hormone provide additional supportive evidence of GH insensitivity in CKD [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IGF-1 is generally synthesized in the liver under the control of GH. Although IGF-1 serum levels in CKD vary from normal (CKD stages 2 through 4) to slightly decreased (CKD stage 5), these levels are inadequately low in the face of elevated circulating GH levels. Experimental animal data demonstrate lower than expected hepatic IGF-1 messenger ribonucleic acid (mRNA) expression in CKD [<a href="#rid29">29</a>]. This hepatic insensitivity to the action of GH appears to be due to reduced GH receptor expression in liver tissue and disturbed GH receptor signalling [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While total immunoreactive IGF-1 levels in serum from children with CKD stages 4 and 5 are normal or slightly decreased, the free IGF-1 (bioactive form) is reduced, and levels correlate with decreasing glomerular filtration rate (GFR) [<a href="#rid33">33-35</a>]. The reduction of bioactive free IGF-1 is due to the increased presence of inhibitory IGF-binding proteins (IGFBP), whose levels inversely correlate with decreasing GFR [<a href="#rid36">36,37</a>]. In patients with CKD, elevated levels of IGFBP are due to a decrease in kidney clearance and increased hepatic production [<a href="#rid29">29,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In CKD, experimental and clinical evidence suggests that the accumulation of high-affinity IGFBPs inhibit IGF action in growth plate chondrocytes by competing with the type 1 IGF receptor in the growth cartilage for binding free IGF [<a href="#rid38">38,39</a>].</p><p></p><p>In addition to the decrease in bioactive free IGF-1 due to inhibitory IGFBPs, there are experimental animal data that suggest a postreceptor defect of IGF-1 signaling contributes to poor growth [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H11319607"><span class="h1">CONTRIBUTING FACTORS</span><span class="headingEndMark"> — </span>In children with CKD, risk factors that contribute to poor growth include anorexia leading to malnutrition [<a href="#rid4">4</a>], fluid and electrolyte abnormalities, metabolic acidosis, CKD-related osteodystrophy, and chronic inflammation  (<a class="graphic graphic_table graphicRef83840" href="/z/d/graphic/83840.html" rel="external">table 2</a>) [<a href="#rid42">42</a>]. However, because children with increasing severity of CKD often have multiple risk factors, it is difficult to ascertain the individual contributions of each of these factors, with the possible exception of inadequate nutrition.</p><p class="headingAnchor" id="H1572073464"><span class="h2">Severity of chronic kidney disease</span><span class="headingEndMark"> — </span>The degree of growth failure increases as kidney function deteriorates  (<a class="graphic graphic_figure graphicRef83841" href="/z/d/graphic/83841.html" rel="external">figure 3</a>) [<a href="#rid18">18</a>]. Patients with end-stage kidney disease (ESKD; stage 5 CKD) are at the greatest risk for poor growth, as they are the most likely to develop the complications of CKD that contribute to impaired growth, which are discussed in the following sections.</p><p class="headingAnchor" id="H11319614"><span class="h2">Inadequate nutrition</span><span class="headingEndMark"> — </span>In children with CKD, inadequate nutritional intake due to anorexia and vomiting is one of the most frequent and important factors contributing to growth failure [<a href="#rid12">12,43</a>].</p><p>In these patients, anorexia may be due to the following causes [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced taste sensation that begins early in the course of CKD and worsens as CKD progresses [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced appetite – Leptin, which acts as an afferent satiety signal, is elevated in children with CKD, presumably due to reduced kidney clearance [<a href="#rid45">45</a>]. There is an inverse linear correlation of plasma leptin levels normalized for body fat mass with spontaneous energy intake in pediatric patients with CKD, suggesting that leptin accumulation contributes to uremic anorexia. In a uremic mice model, elevations in hormonal and inflammatory cytokines including leptin, tumor necrosis factor alpha, interleukin (IL)-1, and IL-6 disrupt signaling pathways within the hypothalamus, which are thought to adversely affect appetite, resulting in a decrease in caloric consumption [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other factors that may compete with nutritional intake include the need to take multiple medications and, in children with polyuria, the preference of water over food.</p><p></p><p>In children with CKD, vomiting is common and is likely due to dysfunctional gastrointestinal motor function, resulting in gastroesophageal reflux and delayed gastric emptying [<a href="#rid43">43,46</a>]. In patients who undergo peritoneal dialysis, the increase in intra-abdominal pressure may also cause vomiting and anorexia.</p><p>Insufficient dietary intake may also result from episodes of fasting surrounding surgical procedures and episodes of sepsis [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H12652650"><span class="h2">Disturbances of water and electrolyte metabolism</span><span class="headingEndMark"> — </span>Many congenital kidney diseases may be associated with fluid and electrolyte abnormalities due to kidney tubular dysfunction that results in polyuria (leading to hypovolemia), and hyponatremia and hypokalemia from excessive loss of sodium and potassium. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Fluid and electrolyte abnormalities'</a>.)</p><p>Although it is difficult to determine the extent to which disturbances in water and electrolyte metabolism contribute to growth failure in individual patients with CKD, these abnormalities can be significant contributors to growth failure. In children with CKD and tubular dysfunction, who have polyuria and salt-wasting, sodium and water supplementation may maintain or improve growth, and potentially delay kidney replacement therapy (KRT) [<a href="#rid47">47</a>]. Additional support is provided by the observation of impaired growth in children with nephronophthisis and fluid and electrolyte abnormalities prior to the development of renal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/6132.html" rel="external">"Clinical manifestations, diagnosis, and treatment of nephronophthisis", section on 'Renal disease'</a>.)</p><p>Experimental data also demonstrate the effect of electrolyte disturbances on growth. In a rat model, sodium deficiency decreases protein synthesis and growth, which is only partially reversible by sodium repletion [<a href="#rid48">48</a>]. Depletion of chloride also causes growth retardation and diminishes muscle protein synthesis [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H11319628"><span class="h2">Metabolic acidosis</span><span class="headingEndMark"> — </span>Metabolic acidosis is almost inevitably observed in CKD stages 3 through 5. This acidosis is primarily due to the kidney's reduced ability to excrete ammonia. The severity of the acidosis can be aggravated by nutritional protein and acid load, catabolism, and kidney tubular dysfunction. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Metabolic acidosis'</a>.)</p><p>Experimental data in uremic animal models demonstrate the effects of metabolic acidosis on the growth hormone/insulin-like growth factor-I (GH/IGF-I) axis as it is associated with down-regulation of spontaneous GH secretion [<a href="#rid50">50</a>], decreased expression of GH receptor and IGF-I messenger ribonucleic acid (mRNA) [<a href="#rid51">51</a>], and a reduction in both baseline and GH-stimulated serum IGF-I concentrations [<a href="#rid52">52</a>]. In addition, metabolic acidosis is associated with increased glucocorticoid production and protein degradation [<a href="#rid53">53-56</a>].</p><p>In an observational study of 1082 children with CKD, metabolic acidosis was associated with a lower height Z-score over time, whereas alkali therapy use was associated with better height Z-scores [<a href="#rid5">5</a>].</p><p>Additional support is provided by the almost universal finding of growth failure in children with metabolic acidosis due to renal tubular acidosis [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">"Etiology and clinical manifestations of renal tubular acidosis in infants and children"</a>.)</p><p class="headingAnchor" id="H11319635"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Children with CKD develop increasing anemia as a result of erythropoietin deficiency. It is not certain if, or to what extent, chronic anemia leads to growth failure. Theoretically, anemia may interfere with growth via various mechanisms, such as poor appetite, intercurrent infections, cardiac complications, and poor oxygenation of cartilage cells in the growth plate. Evidence for anemia as a contributor to growth failure is supported by the observation that transfusion regimens that maintain a near normal hematocrit improve growth in children with growth retardation due to chronic anemia (eg, thalassemia major) [<a href="#rid57">57</a>]. Additionally, hemoglobin decline is associated with growth impairment over time in children with mild to moderate nonglomerular CKD, even before hemoglobin levels reach the cutoffs that are currently used to define anemia in this population [<a href="#rid6">6</a>].</p><p>However, it is less clear that anemia in children with CKD is a significant contributor to growth failure, as correction of anemia with recombinant human erythropoietin has not been shown to improve the growth of children with CKD [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Treatment of anemia'</a>.)</p><p class="headingAnchor" id="H11319642"><span class="h2">Chronic kidney disease-mineral and bone disorder</span><span class="headingEndMark"> — </span>CKD-mineral and bone disorder (CKD-MBD) and osteodystrophy are caused by dysfunctional vitamin D metabolism and by secondary hyperparathyroidism. CKD-related osteodystrophy is manifested clinically as skeletal deformities, muscular hypotension, and, occasionally, slipped capital femoral epiphyses. (See  <a class="medical medical_review" href="/z/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p>In children with CKD, the growth plate is vulnerable to injury with disruption of the connection between the epiphyseal plate and the metaphysis. Although gross skeletal deformities can contribute to the retardation of a child's growth, the appearance of osteodystrophy is not paralleled by alterations in the epiphyseal growth of the long bones. Growth is only arrested completely when secondary hyperparathyroidism results in severe destruction of the metaphyseal bone architecture.</p><p>The extent to which secondary hyperparathyroidism contributes to growth failure is unclear [<a href="#rid59">59</a>]. Low bone turnover induced by relatively low parathyroid hormone (PTH) levels may contribute to growth failure [<a href="#rid60">60</a>]. At the other end of the spectrum, excessive secretion of PTH can lead to the destruction of growth plate architecture, epiphyseal displacement, and metaphyseal fractures [<a href="#rid60">60</a>]. However, treatment of children with CKD with vitamin D or 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) does not stimulate longitudinal growth [<a href="#rid61">61</a>]. Serum PTH levels should be kept within the recommended CKD stage-dependent target range for children [<a href="#rid62">62-64</a>]. (See  <a class="medical medical_review" href="/z/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Management'</a>.)</p><p>Serum concentrations of total 25-hydroxyvitamin D3 should be kept at above 30 ng/mL in all stages of CKD [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H359697173"><span class="h2">Prenatal factors</span><span class="headingEndMark"> — </span>There is an association between poor growth in children with CKD and an abnormal birth history. This was illustrated in a study of 426 children from the Chronic Kidney Disease in Children Study (CKiD) that demonstrated the overall risk of low birth weight (LBW), small for gestational age (SGA), and prematurity was 17, 14, and 12 percent, respectively [<a href="#rid66">66</a>]. A multivariate analysis showed an inverse correlation between current height and weight, and LBW or SGA.</p><p class="headingAnchor" id="H359695448"><span class="h2">Age at onset of chronic kidney disease</span><span class="headingEndMark"> — </span>In general, the younger the age of onset of CKD, the greater is the potential magnitude of growth retardation. This is illustrated by data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) CKD registry that measured height when children were initially enrolled [<a href="#rid18">18</a>]. The percentage of children with significant growth retardation (Z-score for height less than -1.88) increased with decreasing age as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>0 to 1 year of age – 58 percent</p><p class="bulletIndent1"><span class="glyph">●</span>2 to 5 years of age – 41 percent</p><p class="bulletIndent1"><span class="glyph">●</span>6 to 12 years of age – 33 percent</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;12 years of age – 22 percent</p><p></p><p class="headingAnchor" id="H750225"><span class="h3">Infancy</span><span class="headingEndMark"> — </span>Because one-third of total growth occurs in the first two years of life, infants with CKD are at risk for severe growth retardation, which may result in irreversible loss of growth potential [<a href="#rid12">12,18</a>]. In a study of 73 children with onset of CKD before six months of age, the mean Z-height score was -3 at three years of age as a consequence of prenatal factors and poor postnatal growth [<a href="#rid67">67</a>]. In this cohort, approximately one-third of height reduction occurred during fetal life, one-third during the first postnatal months, and the last third between 0.75 and 1.5 years of age.</p><p>The main contributing factor of growth failure for this age group appears to be inadequate nutrition due to anorexia and recurrent vomiting. Supporting data for the influence of nutrition on growth during infancy and early childhood are based on the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, Z-height scores correlated with body cell mass, and serum transferrin and albumin levels (markers of nutritional status) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study from a single tertiary center, intensive nutritional intervention in 101 children with stage 4 or 5 CKD who presented before two years of age improved the mean Z-height score from -2.18 at six months of age to -1.74 and -1.51 at one and two years of age, respectively [<a href="#rid69">69</a>].</p><p></p><p>Other contributors to poor growth during infancy include water and electrolyte abnormalities, metabolic acidosis, and catabolic episodes during acute illnesses (eg, infection).</p><p>However, despite correction or prevention of these conditions and inadequate nutrition, deterioration of growth in infancy may still occur, indicating that the insensitivity to the action of GH is already operative during this period of growth [<a href="#rid12">12</a>]. (See <a class="local">'Pathogenesis: Disturbance of growth hormone/IGF-1 axis'</a> above.)</p><p class="headingAnchor" id="H85209786"><span class="h4">Congenital abnormalities</span><span class="headingEndMark"> — </span>Some infants may have syndromic or congenital causes of CKD with concomitant non-kidney abnormalities that affect growth, such as infantile nephropathic cystinosis.</p><p class="headingAnchor" id="H750232"><span class="h3">Mid-childhood</span><span class="headingEndMark"> — </span>Patients who develop CKD after the second year of life lose relative height early in the course of the disease and subsequently follow this lower growth percentile after stabilization of the disease process. In this group of patients, the impact of the severity of kidney disease is particularly evident. This was illustrated in a prospective study of children with CKD due to kidney hypoplasia/dysplasia followed from birth to 10 years of age that showed a slightly but continuously lower annual growth rate in patients with a glomerular filtration rate (GFR) below 25 mL/min per 1.73 m² compared with patients with a higher GFR [<a href="#rid70">70</a>]. This difference accumulated into a mean height difference of 6 cm between these two groups at the age of 10 years. Multiple variate analysis demonstrated that decreasing GFR was a significant contributor to poor growth.</p><p>Other factors such as inadequate nutrition appear to be less important for poor growth in this age group compared with infancy. In addition, catch-up growth appears to be suppressed in a uremic milieu. It has been proposed that this percentile-parallel growth pattern during the mid-childhood period reflects a net balance between the growth suppressive effect of uremia and the inherent tendency for catch-up growth [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H750239"><span class="h3">Puberty</span><span class="headingEndMark"> — </span>The onset of puberty is usually delayed in adolescents with CKD by an average of 2 to 2.5 years, and approximately two-thirds of adolescents with CKD stage 5 enter puberty beyond the normal age range [<a href="#rid71">71</a>]. As a result, the pubertal growth spurt is also delayed by 2.5 years and the degree of delay correlates with the duration and severity of CKD [<a href="#rid71">71</a>].</p><p>Although there is a distinct acceleration of growth during puberty, the total pubertal height gain is reduced in both sexes to approximately 50 percent of normal late-maturing children. This reduction in height gain is due to a marked suppression of the late pre-spurt height velocity, a subnormal peak height velocity, and a shortening of the pubertal growth period by one year in boys and 1.5 years in girls [<a href="#rid71">71</a>]. Notably, the prolonged prepubertal growth phase, resulting from the delayed onset of the pubertal growth spurt, permits the patients to grow to an almost normal immediate pre-spurt height. However, relative height is subsequently lost during the shortened and less robust pubertal growth spurt, resulting in an average postpubertal Z-height score of -2.9 standard deviations (SD) in males and -2.3 SD in females with CKD stage 5.</p><p>In subsequent studies with advances in CKD management, most children requiring KRT before puberty have normal or only slightly delayed pubertal onset. In two studies, mean age at pubertal onset as well as age at menarche did not differ between children on KRT and healthy children, and serum levels of pubertal reproductive hormones were normal in the great majority of patients with CKD [<a href="#rid20">20,72</a>]. In particular, early kidney transplantation before the onset of puberty prevents delay in pubertal development and improves adult height [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H750246"><span class="h4">Bone maturation</span><span class="headingEndMark"> — </span>Bone maturation continues to be delayed by approximately 1.4 years compared with healthy children, although this does not negatively impact pubertal development [<a href="#rid20">20</a>]. However, alterations of bone maturation may result in loss of height gain during the pubertal growth spurt. In patients undergoing dialysis, bone maturation is increasingly retarded before the start of puberty; however, it accelerates dramatically with the onset of puberty [<a href="#rid73">73,74</a>]. This observation, and the fact that uremic boys respond to exogenous application of <a class="drug drug_pediatric" data-topicid="12827" href="/z/d/drug information/12827.html" rel="external">testosterone</a> esters by an exaggerated increase in skeletal maturation [<a href="#rid74">74</a>], suggest that the sensitivity of the growth plate to sex steroids is conserved. However, because proliferation (ie, growth) cannot keep pace with differentiation (ie, bone maturation), growth potential is irreversibly lost during puberty in advanced CKD.</p><p>In contrast, in many patients after kidney transplantation, an apparent standstill of bone maturation is observed, even when the patient is growing and puberty is progressing. This phenomenon is thought to be related to direct interference of glucocorticoids with the differentiation of the growth plate. Despite the delayed bone age, late growth is usually not observed [<a href="#rid71">71,75</a>]. In fact, the successive stages of the pubertal growth spurt seem to occur at increasingly earlier bone ages than would be assumed in a normal population [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H85209794"><span class="h2">Glucocorticoid therapy</span><span class="headingEndMark"> — </span>Glucocorticoid therapy, particularly daily glucocorticoid therapy, was historically used as immunosuppressive therapy following kidney transplantation. Glucocorticoids are also used in a variety of kidney disease, such as idiopathic nephrotic syndrome (NS). Growth failure is a known major adverse effect of glucocorticoid therapy and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">"Causes of short stature", section on 'Glucocorticoid therapy'</a>.)</p><p class="headingAnchor" id="H85209851"><span class="h1">EVALUATION OF GROWTH</span><span class="headingEndMark"> — </span>In all children with CKD, routine measurements of growth should be obtained that measure the growth velocity in children as it is a more sensitive index of growth than is a single measurement of length/height  (<a class="graphic graphic_figure graphicRef96367" href="/z/d/graphic/96367.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef96366" href="/z/d/graphic/96366.html" rel="external">figure 2</a>). Normal growth velocity varies with age  (<a class="graphic graphic_figure graphicRef70382" href="/z/d/graphic/70382.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/z/d/html/2845.html" rel="external">"Normal growth patterns in infants and prepubertal children", section on 'Growth velocity'</a>.)</p><p>As for any child with a potentially growth-limiting chronic disease, length (before two years of age) and height (from two years of age) should be assessed regularly by trained personnel using standardized techniques with calibrated equipment, which is compared with sex- and age-specific reference charts for healthy children. Gestational age is taken into account when assessing length of infants born preterm. </p><p class="bulletIndent1"><span class="glyph">●</span>For infants or for children when assessment of standing height is not feasible, supine length is measured using a validated length board or mat up to a length of 80 cm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For older children, standing height is measured using a wall-mounted stadiometer.</p><p></p><p>Z-scores of height/length measurement or growth velocity is a conversion that represents the number of standard deviations from the mean values for age and sex based on data for the general population. The Z-score for length/height or growth velocity is commonly used to assess growth in children with CKD. The following calculators are used to determine the Z-score for height for boys and girls, and length in infants (<a class="calc calc_professional" href="/z/d/html/13413.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/13416.html" rel="external">calculator 2</a> and <a class="calc calc_professional" href="/z/d/html/15631.html" rel="external">calculator 3</a>). (See  <a class="medical medical_review" href="/z/d/html/5356.html" rel="external">"Measurement of growth in children", section on 'Use of Z-scores'</a>.)</p><p>In a 2009 revision of the nutritional guidelines for children with CKD, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative recommended that the frequency of growth measurements and nutritional assessment be based on the age of the patient and the CKD stage  (<a class="graphic graphic_table graphicRef52366" href="/z/d/graphic/52366.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef89808" href="/z/d/graphic/89808.html" rel="external">table 1</a>) [<a href="#rid76">76</a>]. In general, assessment is performed at least twice as frequently as would be performed in a healthy child of the same age.</p><p class="headingAnchor" id="H85210653"><span class="h1">DIAGNOSIS OF GROWTH FAILURE</span><span class="headingEndMark"> — </span>The diagnoses of short stature and growth failure in children with CKD are based upon the following definitions [<a href="#rid76">76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Short stature is defined as a length/height Z-score &lt;-1.88 or a length/height for age &lt;3<sup>rd</sup> percentile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Growth failure is defined as height velocity Z-score &lt;-1.88 or a height velocity for age &lt;3<sup>rd</sup> percentile that persists beyond three months.</p><p></p><p class="headingAnchor" id="H85210702"><span class="h1">FURTHER EVALUATION TO IDENTIFY UNDERLYING RISK FACTORS</span><span class="headingEndMark"> — </span>Further evaluation is undertaken to detect any of the following risk factors for growth failure, which are amenable to treatment (see <a class="local">'Contributing factors'</a> above and  <a class="medical medical_review" href="/z/d/html/83284.html" rel="external">"Growth failure in children with chronic kidney disease: Prevention and management", section on 'Supportive measures'</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional assessment to determine if there is adequate energy intake  (<a class="graphic graphic_table graphicRef56276" href="/z/d/graphic/56276.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes and venous blood gas to evaluate pH, carbon dioxide (PaCO<sub>2</sub>), and the bicarbonate to detect any electrolyte abnormality or metabolic acidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count to detect anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calculation of glomerular filtration rate (GFR) using serum creatinine and height to assess kidney function [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium, phosphorus and parathyroid hormone level, and if appropriate, 25-hydroxyvitamin D levels to assess bone mineral metabolism and detect secondary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p></p><p class="headingAnchor" id="H213165080"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110751.html" rel="external">"Society guideline links: Chronic kidney disease in children"</a>.)</p><p class="headingAnchor" id="H11319727"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance</strong> – Growth failure is a major complication of children with chronic kidney disease (CKD). Poor growth in children with CKD is associated with increased morbidity (eg, increased hospitalization rate, decreased school attendance, and poorer physical function) and increased mortality. Growth failure results in adult short stature, which contributes to a lower perceived quality of life and self-esteem. (See <a class="local">'Impact of poor growth'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Approximately one-third of children with CKD have evidence of short stature (ie, height &lt;3<sup>rd</sup> percentile for age and sex). The risk for poor growth increases with decreasing kidney function  (<a class="graphic graphic_figure graphicRef83841" href="/z/d/graphic/83841.html" rel="external">figure 3</a>). (See <a class="local">'Prevalence'</a> above and <a class="local">'Severity of chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contributing factors</strong> – Important factors that contribute to growth failure in children with CKD include (see <a class="local">'Contributing factors'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severity and age of onset of CKD</strong> – The degree of growth failure increases as kidney function deteriorates  (<a class="graphic graphic_figure graphicRef83841" href="/z/d/graphic/83841.html" rel="external">figure 3</a>). Patients with end-stage kidney disease (ESKD; stage 5 CKD) are at the greatest risk for poor growth. In general, the younger the age at onset of CKD, the greater is the potential impact on growth retardation. As a result, patients who present with CKD in infancy are at higher risk for growth failure compared with older children. (See <a class="local">'Severity of chronic kidney disease'</a> above and <a class="local">'Age at onset of chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other factors</strong> – Other important contributing factors include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Inadequate nutrition (see <a class="local">'Inadequate nutrition'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Metabolic acidosis (see <a class="local">'Metabolic acidosis'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Fluid and electrolyte abnormalities (see <a class="local">'Disturbances of water and electrolyte metabolism'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Chronic anemia (see <a class="local">'Anemia'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>CKD-related osteodystrophy (see <a class="local">'Chronic kidney disease-mineral and bone disorder'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoid therapy (see <a class="local">'Glucocorticoid therapy'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of growth</strong> – For each child with CKD, ongoing assessment of growth is based on determining the growth velocity between visits. These measurements can be converted to Z-scores of height/length measurement or growth velocity that represent the number of standard deviations from the mean values for age and sex based on data for the general population  (<a class="graphic graphic_figure graphicRef96367" href="/z/d/graphic/96367.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef96366" href="/z/d/graphic/96366.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef70382" href="/z/d/graphic/70382.html" rel="external">figure 4</a>). (See <a class="local">'Evaluation of growth'</a> above.)</p><p></p><p class="bulletIndent1">The following calculators can be used to determine the Z-score for height:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants (<a class="calc calc_professional" href="/z/d/html/15631.html" rel="external">calculator 3</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>For boys (<a class="calc calc_professional" href="/z/d/html/13413.html" rel="external">calculator 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>For girls (<a class="calc calc_professional" href="/z/d/html/13416.html" rel="external">calculator 2</a>)</p><p></p><p class="bulletIndent1">The frequency of growth assessment is based on the age of the patient and the severity of their kidney disease (ie, CKD staging)  (<a class="graphic graphic_table graphicRef52366" href="/z/d/graphic/52366.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef89808" href="/z/d/graphic/89808.html" rel="external">table 1</a>). (See <a class="local">'Evaluation of growth'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnoses of short stature and growth failure in children with CKD are based upon the following definitions. (See <a class="local">'Diagnosis of growth failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Short stature is defined as a length/height Z-score &lt;-1.88 or a length/height for age &lt;3<sup>rd</sup> percentile.</p><p class="bulletIndent2"><span class="glyph">•</span>Growth failure is defined as height velocity Z-score &lt;-1.88 or a height velocity for age &lt;3<sup>rd</sup> percentile that persists beyond three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation</strong> – Further evaluation is focused on detecting risk factors for growth failure that are amenable to treatment. This consists of nutritional assessment and laboratory tests, including complete blood count, serum electrolytes, venous blood gas (to assess pH, carbon dioxide [PaCO<sub>2</sub>], and bicarbonate levels), creatinine, calcium, phosphorus, and parathyroid hormone (PTH) levels. (See <a class="local">'Further evaluation to identify underlying risk factors'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mahan JD, Warady BA, Consensus Committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 2006; 21:917.</a></li><li><a class="nounderline abstract_t">André JL, Bourquard R, Guillemin F, et al. Final height in children with chronic renal failure who have not received growth hormone. Pediatr Nephrol 2003; 18:685.</a></li><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.</a></li><li><a class="nounderline abstract_t">Wong CS, Gipson DS, Gillen DL, et al. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis 2000; 36:811.</a></li><li><a class="nounderline abstract_t">Furth SL, Hwang W, Yang C, et al. Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol 2002; 17:450.</a></li><li><a class="nounderline abstract_t">Furth SL, Stablein D, Fine RN, et al. Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 2002; 109:909.</a></li><li><a class="nounderline abstract_t">Rosenkranz J, Reichwald-Klugger E, Oh J, et al. Psychosocial rehabilitation and satisfaction with life in adults with childhood-onset of end-stage renal disease. Pediatr Nephrol 2005; 20:1288.</a></li><li><a class="nounderline abstract_t">Gerson AC, Wentz A, Abraham AG, et al. Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics 2010; 125:e349.</a></li><li><a class="nounderline abstract_t">Al-Uzri A, Matheson M, Gipson DS, et al. The impact of short stature on health-related quality of life in children with chronic kidney disease. J Pediatr 2013; 163:736.</a></li><li><a class="nounderline abstract_t">Broyer M, Le Bihan C, Charbit M, et al. Long-term social outcome of children after kidney transplantation. Transplantation 2004; 77:1033.</a></li><li><a class="nounderline abstract_t">Rees L, Mak RH. Nutrition and growth in children with chronic kidney disease. Nat Rev Nephrol 2011; 7:615.</a></li><li><a class="nounderline abstract_t">Wühl E, Haffner D, Offner G, et al. Long-term treatment with growth hormone in short children with nephropathic cystinosis. J Pediatr 2001; 138:880.</a></li><li><a class="nounderline abstract_t">Busschbach JJ, Rikken B, Grobbee DE, et al. Quality of life in short adults. Horm Res 1998; 49:32.</a></li><li><a class="nounderline abstract_t">Mehls O, Wühl E, Tönshoff B, et al. Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr 2008; 97:1159.</a></li><li><a class="nounderline abstract_t">Harambat J, Bonthuis M, van Stralen KJ, et al. Adult height in patients with advanced CKD requiring renal replacement therapy during childhood. Clin J Am Soc Nephrol 2014; 9:92.</a></li><li class="breakAll">NAPRTCS 2014 Annual Report. EMMES Corporation, Rockville.</li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies 2008 Annual Report: Renal transplantation, dialysis, and chronic renal insufficiency. https://web.emmes.com/study/ped/annlrept/Annual%20Report%20-2008.pdf (Accessed on April 12, 2012).</li><li class="breakAll">North American Pediatric Renal Tranplant Colloborative Studies  2011 Annual review. Dialysis https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.</li><li><a class="nounderline abstract_t">Franke D, Winkel S, Gellermann J, et al. Growth and maturation improvement in children on renal replacement therapy over the past 20 years. Pediatr Nephrol 2013; 28:2043.</a></li><li><a class="nounderline abstract_t">Klare B, Montoya CR, Fischer DC, et al. Normal adult height after steroid-withdrawal within 6 months of pediatric kidney transplantation: a 20 years single center experience. Transpl Int 2012; 25:276.</a></li><li><a class="nounderline abstract_t">Hartung EA, Furth SL. Growth in children on renal replacement therapy: a shrinking problem? Pediatr Nephrol 2013; 28:1905.</a></li><li><a class="nounderline abstract_t">Rees L, Azocar M, Borzych D, et al. Growth in very young children undergoing chronic peritoneal dialysis. J Am Soc Nephrol 2011; 22:2303.</a></li><li><a class="nounderline abstract_t">Tönshoff B, Kiepe D, Ciarmatori S. Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol 2005; 20:279.</a></li><li><a class="nounderline abstract_t">Samaan NA, Freeman RM. Growth hormone levels in severe renal failure. Metabolism 1970; 19:102.</a></li><li><a class="nounderline abstract_t">Pimstone BL, Le Roith D, Epstein S, Kronheim S. Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease. J Clin Endocrinol Metab 1975; 41:392.</a></li><li><a class="nounderline abstract_t">Davidson MB, Fisher MB, Dabir-Vaziri N, Schaffer M. Effect of protein intake and dialysis on the abnormal growth hormone, glucose, and insulin homeostasis in uremia. Metabolism 1976; 25:455.</a></li><li><a class="nounderline abstract_t">Mak RH, Cheung WW, Roberts CT Jr. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease. Growth Horm IGF Res 2008; 18:17.</a></li><li><a class="nounderline abstract_t">Tönshoff B, Powell DR, Zhao D, et al. Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 1997; 138:938.</a></li><li><a class="nounderline abstract_t">Chan W, Valerie KC, Chan JC. Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake. Kidney Int 1993; 43:790.</a></li><li><a class="nounderline abstract_t">Tönshoff B, Edén S, Weiser E, et al. Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia. Kidney Int 1994; 45:1085.</a></li><li><a class="nounderline abstract_t">Schaefer F, Chen Y, Tsao T, et al. Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia. J Clin Invest 2001; 108:467.</a></li><li><a class="nounderline abstract_t">Phillips LS, Fusco AC, Unterman TG, del Greco F. Somatomedin inhibitor in uremia. J Clin Endocrinol Metab 1984; 59:764.</a></li><li><a class="nounderline abstract_t">Blum WF, Ranke MB, Kietzmann K, et al. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol 1991; 5:539.</a></li><li><a class="nounderline abstract_t">Frystyk J, Ivarsen P, Skjaerbaek C, et al. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999; 56:2076.</a></li><li><a class="nounderline abstract_t">Ulinski T, Mohan S, Kiepe D, et al. Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 in children with chronic renal failure: relationship to growth and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Pediatr Nephrol 2000; 14:589.</a></li><li><a class="nounderline abstract_t">Tönshoff B, Blum WF, Wingen AM, Mehls O. Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Clin Endocrinol Metab 1995; 80:2684.</a></li><li><a class="nounderline abstract_t">Kiepe D, Ulinski T, Powell DR, et al. Differential effects of insulin-like growth factor binding proteins-1, -2, -3, and -6 on cultured growth plate chondrocytes. Kidney Int 2002; 62:1591.</a></li><li><a class="nounderline abstract_t">Kiepe D, Andress DL, Mohan S, et al. Intact IGF-binding protein-4 and -5 and their respective fragments isolated from chronic renal failure serum differentially modulate IGF-I actions in cultured growth plate chondrocytes. J Am Soc Nephrol 2001; 12:2400.</a></li><li><a class="nounderline abstract_t">Ding H, Gao XL, Hirschberg R, et al. Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest 1996; 97:1064.</a></li><li><a class="nounderline abstract_t">Tsao T, Fervenza F, Friedlaender M, et al. Effect of prolonged uremia on insulin-like growth factor-I receptor autophosphorylation and tyrosine kinase activity in kidney and muscle. Exp Nephrol 2002; 10:285.</a></li><li><a class="nounderline abstract_t">Mak RH, Cheung W, Cone RD, Marks DL. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 2006; 69:794.</a></li><li><a class="nounderline abstract_t">Ravelli AM, Ledermann SE, Bisset WM, et al. Foregut motor function in chronic renal failure. Arch Dis Child 1992; 67:1343.</a></li><li><a class="nounderline abstract_t">Armstrong JE, Laing DG, Wilkes FJ, Kainer G. Smell and taste function in children with chronic kidney disease. Pediatr Nephrol 2010; 25:1497.</a></li><li><a class="nounderline abstract_t">Daschner M, Tönshoff B, Blum WF, et al. Inappropriate elevation of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Am Soc Nephrol 1998; 9:1074.</a></li><li><a class="nounderline abstract_t">Kari JA, Gonzalez C, Ledermann SE, et al. Outcome and growth of infants with severe chronic renal failure. Kidney Int 2000; 57:1681.</a></li><li><a class="nounderline abstract_t">Parekh RS, Flynn JT, Smoyer WE, et al. Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy. J Am Soc Nephrol 2001; 12:2418.</a></li><li><a class="nounderline abstract_t">Wassner SJ. The effect of sodium repletion on growth and protein turnover in sodium-depleted rats. Pediatr Nephrol 1991; 5:501.</a></li><li><a class="nounderline abstract_t">Heinly MM, Wassner SJ. The effect of isolated chloride depletion on growth and protein turnover in young rats. Pediatr Nephrol 1994; 8:555.</a></li><li><a class="nounderline abstract_t">Challa A, Krieg RJ Jr, Thabet MA, et al. Metabolic acidosis inhibits growth hormone secretion in rats: mechanism of growth retardation. Am J Physiol 1993; 265:E547.</a></li><li><a class="nounderline abstract_t">Challa A, Chan W, Krieg RJ Jr, et al. Effect of metabolic acidosis on the expression of insulin-like growth factor and growth hormone receptor. Kidney Int 1993; 44:1224.</a></li><li><a class="nounderline abstract_t">Brüngger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in humans. Kidney Int 1997; 51:216.</a></li><li><a class="nounderline abstract_t">May RC, Kelly RA, Mitch WE. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J Clin Invest 1986; 77:614.</a></li><li><a class="nounderline abstract_t">Williams B, Layward E, Walls J. Skeletal muscle degradation and nitrogen wasting in rats with chronic metabolic acidosis. Clin Sci (Lond) 1991; 80:457.</a></li><li><a class="nounderline abstract_t">Bailey JL, Wang X, England BK, et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996; 97:1447.</a></li><li><a class="nounderline abstract_t">May RC, Hara Y, Kelly RA, et al. Branched-chain amino acid metabolism in rat muscle: abnormal regulation in acidosis. Am J Physiol 1987; 252:E712.</a></li><li><a class="nounderline abstract_t">Kattamis CA, Kattamis AC. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination. Semin Hematol 1995; 32:269.</a></li><li><a class="nounderline abstract_t">Jabs K. The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 1996; 10:324.</a></li><li><a class="nounderline abstract_t">Waller S. Parathyroid hormone and growth in chronic kidney disease. Pediatr Nephrol 2011; 26:195.</a></li><li><a class="nounderline abstract_t">Schmitt CP, Mehls O. Mineral and bone disorders in children with chronic kidney disease. Nat Rev Nephrol 2011; 7:624.</a></li><li><a class="nounderline abstract_t">Chesney RW, Hamstra A, Jax DK, et al. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy. Contrib Nephrol 1980; 18:55.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.</a></li><li><a class="nounderline abstract_t">Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21:151.</a></li><li><a class="nounderline abstract_t">Haffner D, Schaefer F. Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies. Pediatr Nephrol 2013; 28:537.</a></li><li><a class="nounderline abstract_t">Shroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. Nephrol Dial Transplant 2017; 32:1098.</a></li><li><a class="nounderline abstract_t">Greenbaum LA, Muñoz A, Schneider MF, et al. The association between abnormal birth history and growth in children with CKD. Clin J Am Soc Nephrol 2011; 6:14.</a></li><li><a class="nounderline abstract_t">Karlberg J, Schaefer F, Hennicke M, et al. Early age-dependent growth impairment in chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. Pediatr Nephrol 1996; 10:283.</a></li><li><a class="nounderline abstract_t">Jones RW, Rigden SP, Barratt TM, Chantler C. The effects of chronic renal failure in infancy on growth, nutritional status and body composition. Pediatr Res 1982; 16:784.</a></li><li><a class="nounderline abstract_t">Mekahli D, Shaw V, Ledermann SE, Rees L. Long-term outcome of infants with severe chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:10.</a></li><li><a class="nounderline abstract_t">Schaefer F, Wingen AM, Hennicke M, et al. Growth charts for prepubertal children with chronic renal failure due to congenital renal disorders. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. Pediatr Nephrol 1996; 10:288.</a></li><li><a class="nounderline abstract_t">Schaefer F, Seidel C, Binding A, et al. Pubertal growth in chronic renal failure. Pediatr Res 1990; 28:5.</a></li><li><a class="nounderline abstract_t">Tainio J, Qvist E, Vehmas R, et al. Pubertal development is normal in adolescents after renal transplantation in childhood. Transplantation 2011; 92:404.</a></li><li><a class="nounderline abstract_t">Betts PR, White RH. Growth potential and skeletal maturity in children with chronic renal insufficiency. Nephron 1976; 16:325.</a></li><li><a class="nounderline abstract_t">Van Steenbergen MW, Wit JM, Donckerwolcke RA. Testosterone esters advance skeletal maturation more than growth in short boys with chronic renal failure and delayed puberty. Eur J Pediatr 1991; 150:676.</a></li><li><a class="nounderline abstract_t">van Diemen-Steenvoorde R, Donckerwolcke RA, Brackel H, et al. Growth and sexual maturation in children after kidney transplantation. J Pediatr 1987; 110:351.</a></li><li><a class="nounderline abstract_t">KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629.</a></li></ol></div><div id="topicVersionRevision">Topic 14555 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16773402" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12750982" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Final height in children with chronic renal failure who have not received growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007685" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Anthropometric measures and risk of death in children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12107811" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Growth failure, risk of hospitalization and death for children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986455" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942781" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Psychosocial rehabilitation and satisfaction with life in adults with childhood-onset of end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083528" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Health-related quality of life of children with mild to moderate chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23628375" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The impact of short stature on health-related quality of life in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15087767" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term social outcome of children after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947116" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nutrition and growth in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391333" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term treatment with growth hormone in short children with nephropathic cystinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9438783" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Quality of life in short adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18624988" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Growth hormone treatment in short children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24178977" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adult height in patients with advanced CKD requiring renal replacement therapy during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24178977" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adult height in patients with advanced CKD requiring renal replacement therapy during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24178977" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Adult height in patients with advanced CKD requiring renal replacement therapy during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24178977" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adult height in patients with advanced CKD requiring renal replacement therapy during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23708760" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Growth and maturation improvement in children on renal replacement therapy over the past 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187956" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Normal adult height after steroid-withdrawal within 6 months of pediatric kidney transplantation: a 20 years single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23793884" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Growth in children on renal replacement therapy: a shrinking problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021715" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Growth in very young children undergoing chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692833" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Growth hormone/insulin-like growth factor system in children with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5410941" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Growth hormone levels in severe renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1159052" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1263839" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of protein intake and dialysis on the abnormal growth hormone, glucose, and insulin homeostasis in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826224" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The growth hormone-insulin-like growth factor-I axis in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9048593" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8479114" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8007578" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489940" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6384255" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Somatomedin inhibitor in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1716946" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594783" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10912524" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 in children with chronic renal failure: relationship to growth and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. German Study Group for Growth Hormone Treatment in Chronic Renal Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7545697" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12371959" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Differential effects of insulin-like growth factor binding proteins-1, -2, -3, and -6 on cultured growth plate chondrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675416" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intact IGF-binding protein-4 and -5 and their respective fragments isolated from chronic renal failure serum differentially modulate IGF-I actions in cultured growth plate chondrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613530" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12097832" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of prolonged uremia on insulin-like growth factor-I receptor autophosphorylation and tyrosine kinase activity in kidney and muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518340" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Leptin and inflammation-associated cachexia in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1471884" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Foregut motor function in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20446097" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Smell and taste function in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9621291" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Inappropriate elevation of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10760104" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcome and growth of infants with severe chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675418" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1716945" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of sodium repletion on growth and protein turnover in sodium-depleted rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7529521" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effect of isolated chloride depletion on growth and protein turnover in young rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238328" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Metabolic acidosis inhibits growth hormone secretion in rats: mechanism of growth retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8301923" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of metabolic acidosis on the expression of insulin-like growth factor and growth hormone receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995736" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511100" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1851685" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Skeletal muscle degradation and nitrogen wasting in rats with chronic metabolic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8617877" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3591935" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Branched-chain amino acid metabolism in rat muscle: abnormal regulation in acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8560284" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8792397" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The effects of recombinant human erythropoietin on growth and nutritional status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20694820" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Parathyroid hormone and growth in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947120" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mineral and bone disorders in children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7353380" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644521" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247644" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893310" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28873969" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030583" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The association between abnormal birth history and growth in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8792391" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Early age-dependent growth impairment in chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7133814" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The effects of chronic renal failure in infancy on growth, nutritional status and body composition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965538" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term outcome of infants with severe chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8792392" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Growth charts for prepubertal children with chronic renal failure due to congenital renal disorders. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2377395" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pubertal growth in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21709603" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pubertal development is normal in adolescents after renal transplantation in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/177898" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Growth potential and skeletal maturity in children with chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1915524" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Testosterone esters advance skeletal maturation more than growth in short boys with chronic renal failure and delayed puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546648" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Growth and sexual maturation in children after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231749" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158356" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : New equations to estimate GFR in children with CKD.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
